• Aucun résultat trouvé

[PDF] Top 20 How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

Has 10000 "How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer" found on our website. Below are the top 20 most common "How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer".

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

... remains for some patients with HER2? breast cancers in the adjuvant setting given that approximately one third of them remain at risk of disease recurrence and metastasis ... Voir le document complet

14

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

... pertuzumab to standard chemotherapy plus trastuzumab in HER2-positive early- stage BC; the number of OS events to date remains rela- tively ...comprehensive HER2 blockade using ... Voir le document complet

12

The human epidermal growth factor receptor 2 (HER2) in the breast cancer : from measurement to targeted treatment

The human epidermal growth factor receptor 2 (HER2) in the breast cancer : from measurement to targeted treatment

... belonging to the family of epidermal growth factor receptors (EGFR) ...the HER2 (ERBB2) gene, which is located on the long arm of chromosome 17 ...(2). HER2 is an essential mediator of cell ... Voir le document complet

334

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

... is to identify the population of interest, in which the decision of adjuvant chemotherapy is dif ficult using only classical clinicopathological ...data. With experi- mented anatomopathologists and ... Voir le document complet

22

The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer

The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer

... lysed for 30 min at 4 uC in 10% glycerol, ...transferred to nitrocel- lulose membrane (GE-Healthcare, Little Chalfont, UK). For HER3 and Phospho-HER3 detection, 80 m g of lysates were ...blocked ... Voir le document complet

13

What do we learn from HER2-positive breast cancer genomic profiles?

What do we learn from HER2-positive breast cancer genomic profiles?

... Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu ...2--positive breast cancer reveals a gene signature prognostic of ... Voir le document complet

7

Under-treatment of elderly patients with ovarian cancer: a population based study

Under-treatment of elderly patients with ovarian cancer: a population based study

... according to the 2011 census). The registry records all cases of cancer oc- curring in this department in a continuous and exhaust- ive ...ovarian cancer included in the present study were validated ... Voir le document complet

11

Prospective study of the energy balance disruption during adjuvant chemotherapy in post-menopausal early-stage breast cancer patient

Prospective study of the energy balance disruption during adjuvant chemotherapy in post-menopausal early-stage breast cancer patient

... Chemoprevention with Bioactive Natural Products ...substances for cancer prevention or as adjuncts to conventional anticancer ...reported to possess the cancer ... Voir le document complet

54

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment

... into cancer tissue and induce normalization of the tumor vasculature ...prognostic for increased survival. In the current study, the number of patients, the short follow-up time and the subsequent ... Voir le document complet

15

Increased macroH2A1.1 Expression Correlates with Poor Survival of Triple-Negative Breast Cancer Patients

Increased macroH2A1.1 Expression Correlates with Poor Survival of Triple-Negative Breast Cancer Patients

... available for 383 of the 579 TNBC samples from the GSE31519 ...surgery to the distinct survival endpoint used in the individual ...sponding to the RFS endpoint, but measured with respect ... Voir le document complet

13

Multimodal nanovectors with a theranostic potential for cancer treatment

Multimodal nanovectors with a theranostic potential for cancer treatment

... image-monitored treatment are the basis of the so called theranostic strategies which are being actively ...developed. For more efficient and accurate diagnosis, magnetic resonance imaging (MRI), computed ... Voir le document complet

3

Breast cancer: Do contaminants conspire with tumors?

Breast cancer: Do contaminants conspire with tumors?

... models for breast cancer are able to recreate the particular interactions of the hormone-dependent cancer, whether cellular or animal models, since they are often too ... Voir le document complet

3

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis

... when treatment for breast cancer is individualized, it seems that the choice of adjuvant treatment in patients with residual disease after NAC should also be ... Voir le document complet

16

Patients with disorders of consciousness: how to treat them?

Patients with disorders of consciousness: how to treat them?

... disorders of consciousness | behavioural evaluation | electrophysiology | neuroimaging | methods, ethics & quality of life | perspectives.. Transcranial direct current stimulation.[r] ... Voir le document complet

21

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

... filter to remove FFPE-related artifacts ​ 57​ ...realigned with Novoalign (see URLs) to filter out false positive that are due to regions of low reliability in the reads ...technology ... Voir le document complet

42

Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer

Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer

... of patients with BM from BC, but are the only trials to provide information related to this type of therapeutic ...survival for patients with controlled extra-cranial ... Voir le document complet

16

Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

... before treatment and 9 months after, on fibular, tibial, median and ulnar nerves  5  .... Treatment was considered efficient only when ONLS score decreased by at least 1 point at ... Voir le document complet

8

Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28].

Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28].

... with CDK4/6 inhibitors ” [Cancer Treatm. Rev. 74 (2019) 21–28] Stefano Fogli a , ⁎ , Marzia Del Re a , Giuseppe Curigliano b , c , Ron H. van Schaik d , Patrizio Lancellotti e , Romano Danesi a a Unit of ... Voir le document complet

1

Detection of HER2+ breast cancer cells using bioinspired DNA-based signal amplification

Detection of HER2+ breast cancer cells using bioinspired DNA-based signal amplification

... circuits for sensitive detection of viable HER2 + breast cancer cells under clinically relevant ...constructed with shorter sequences compared to previously reported HCR systems, ... Voir le document complet

7

Detection of HER2+ breast cancer cells using bioinspired DNA-based signal amplification

Detection of HER2+ breast cancer cells using bioinspired DNA-based signal amplification

... Sarah D. Rafiee + , Samet Kocabey + , Michael Mayer, Jonathan List,* and Curzio Rüegg*© 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative ... Voir le document complet

13

Show all 10000 documents...